Lin Shao-Lee — SEC insider filings
SEC reporting owner CIK 1725092. 20 insider filings on record with FilingPulse; latest filed 2026-10-14.
Transaction summary — filings shown
Covers all 20 filings on record, filed 2020-09-28 to 2026-10-14. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 10 legs across 5 filings — 105,698 shares, $2,176,668 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 42.
- Largest priced transaction: sale of 34,225 shares @ $26.99 ($923,733) in Cue Biopharma, Inc., filed 2026-08-14.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | Chief Executive Officer, Director | 6 | — | 7 legs · 69,345 sh · $1,912,053 | 10 |
| ACELYRIN, Inc. (SLRN) | Chief Executive Officer, Director | 8 | — | 3 legs · 36,353 sh · $264,616 | 24 |
| Surrozen, Inc./DE (SRZN) | Director | 4 | — | — | 4 |
| Principia Biopharma Inc. (PRNB) | Director | 1 | — | — | 3 |
| Third Harmonic Bio, Inc. (THRD) | Director | 1 | — | — | 1 |
Insider filings — Lin Shao-Lee
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-14 | 4 | Cue Biopharma, Inc. (CUE) | Sale (S): 10,000 @ $27.50 · Sale (S): 1,087 @ $28.05 | EDGAR |
| 2026-08-14 | 4 | Cue Biopharma, Inc. (CUE) | Option exercise (M): 109,179 @ $0 · Sale (S): 34,225 @ $26.99 · Sale (S): 5,775 @ $27.75 · Sale (S): 5,423 @ $27.19 · Sale (S): 2,375 @ $28.11 · Sale (S): 10,460 @ $29.48 · +1 more | EDGAR |
| 2026-07-30 | 4/A | Cue Biopharma, Inc. (CUE) | Grant/award (A): 90,906 (derivative) @ $11 · Grant/award (A): 45,453 (derivative) | EDGAR |
| 2026-07-10 | 4 | Cue Biopharma, Inc. (CUE) | Grant/award (A): 327,537 @ $0 · Grant/award (A): 327,537 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | Cue Biopharma, Inc. (CUE) | Purchase (P): 90,906 (derivative) @ $11 · Purchase (P): 45,453 (derivative) | EDGAR |
| 2026-05-07 | 4 | Cue Biopharma, Inc. (CUE) | Grant/award (A): 327,537 @ $0 · Grant/award (A): 655,074 (derivative) @ $0 | EDGAR |
| 2025-05-15 | 4 | Surrozen, Inc./DE (SRZN) | Grant/award (A): 1,333 (derivative) @ $0 | EDGAR |
| 2024-06-06 | 4 | Surrozen, Inc./DE (SRZN) | Grant/award (A): 1,333 (derivative) @ $0 | EDGAR |
| 2024-04-03 | 4 | ACELYRIN, Inc. (SLRN) | Sale (S): 9,961 @ $6.63 | EDGAR |
| 2024-02-22 | 4 | ACELYRIN, Inc. (SLRN) | Sale (S): 15,701 @ $7.60 | EDGAR |
| 2024-01-11 | 4 | ACELYRIN, Inc. (SLRN) | Grant/award (A): 964,829 (derivative) @ $0 · Grant/award (A): 413,498 (derivative) @ $0 | EDGAR |
| 2024-01-04 | 4 | ACELYRIN, Inc. (SLRN) | Sale (S): 10,691 @ $7.41 | EDGAR |
| 2023-10-06 | 4 | ACELYRIN, Inc. (SLRN) | Other (J): 1,161,747 @ $0 · Other (J): 132,236 @ $0 | EDGAR |
| 2023-08-18 | 4 | ACELYRIN, Inc. (SLRN) | Grant/award (A): 842,400 @ $0 | EDGAR |
| 2023-05-19 | 4 | Surrozen, Inc./DE (SRZN) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2023-05-11 | 4 | ACELYRIN, Inc. (SLRN) | Conversion (C): 1,161,747 · Other (J): 1,107,213 @ $0 · Other (J): 1,107,213 @ $0 · Tax withholding (F): 337,179 @ $24.69 · Other (J): 677,813 @ $0 · Other (J): 677,813 @ $0 · +12 more | EDGAR |
| 2023-05-04 | 4 | ACELYRIN, Inc. (SLRN) | Grant/award (A): 774,788 (derivative) @ $0 | EDGAR |
| 2022-10-27 | 4 | Third Harmonic Bio, Inc. (THRD) | Grant/award (A): 13,667 (derivative) @ $0 | EDGAR |
| 2022-06-09 | 4 | Surrozen, Inc./DE (SRZN) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2020-09-28 | 4 | Principia Biopharma Inc. (PRNB) | Disposition to issuer (D): 20,475 (derivative) · Disposition to issuer (D): 10,240 (derivative) · Disposition to issuer (D): 10,240 (derivative) | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-09-28 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1725092 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs